Importantly, loss or reduction of dystroglycan is also emerging as a common event in the progression of epithelial derived cancers, including breast, prostate, colon, cervical, and renal adenocarcinomas (Cross et al., 2008; Esser et al., 2013; Sgambato et al., 2007, 2003, 2006). This evidence concerns the gene DAG1 and papillary renal cell carcinoma.